15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
23:09 , May 17, 2019 |  BC Extra  |  Politics & Policy

Friends, Parker Institute call for more flexibility in early T cell therapy development

Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy recommend more flexible IND and manufacturing requirements and the use of adaptive clinical trials to advance development of emerging cellular therapeutics such as CAR...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
14:00 , Apr 11, 2019 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:22 , Dec 22, 2018 |  BioCentury  |  Finance

Venture surge

Venture capital investments in the life sciences surged to more than $20 billion worldwide in 2018, with VCs increasingly concentrating their disbursements in nine-digit megarounds, some of which preceded IPOs later in the year. Through...
20:20 , Dec 21, 2018 |  BC Week In Review  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
22:54 , Dec 20, 2018 |  BC Extra  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
22:36 , Dec 7, 2018 |  BioCentury  |  Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...